

# Association of glial and neuronal degeneration markers with Alzheimer's disease cerebrospinal fluid profile and cognitive functions

Unnur D. Teitsdottir (✉ [udt1@hi.is](mailto:udt1@hi.is))

University of Iceland <https://orcid.org/0000-0003-2723-2242>

**Maria K. Jonsdottir**

1) Department of Psychology, Reykjavik University, Reykjavik, Iceland, 2) Department of Psychiatry, Landspítali - National University Hospital, Reykjavik, Iceland

**Sigrun H. Lund**

deCode genetics/Amgen, Inc., Reykjavik, Iceland

**Taher Darreh-Shori**

Division of Clinical Geriatrics, Center for Alzheimer Research, NVS Department, Karolinska Institutet, Huddinge, Sweden

**Jon Snaedal**

Memory Clinic, Department of Geriatric Medicine, Landspítali - National University Hospital, Reykjavik, Iceland

**Petur H. Petersen**

Faculty of Medicine, Department of Anatomy, Biomedical Center, University of Iceland, Reykjavik, Iceland

---

## Research

**Keywords:** Alzheimer's disease, Cerebrospinal fluid, Neurofilament light, YKL-40, S100 calcium-binding protein B, Glial fibrillary acidic protein, AD biomarker profile, Cognitive domains

**Posted Date:** July 8th, 2020

**DOI:** <https://doi.org/10.21203/rs.2.19886/v2>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published on August 4th, 2020. See the published version at <https://doi.org/10.1186/s13195-020-00657-8>.

# Abstract

**Background** Neuroinflammation has gained increasing attention as a potential contributing factor in the onset and progression of Alzheimer's disease (AD). The objective of this study was to examine the association of selected cerebrospinal fluid (CSF) inflammatory and neuronal degeneration markers with signature CSF AD profile and cognitive functions among subjects at the symptomatic pre- and early dementia stages. **Methods** In this cross-sectional study, 52 subjects were selected from an Icelandic memory clinic cohort. Subjects were classified as having CSF AD (n=28, age=67, 33% female, Mini-mental state examination [MMSE]=28) or non-AD (n=24, age=70, 39% female, MMSE=27) profile based on the ratio between CSF total-tau (T-tau) and amyloid- $\beta$  1-42 (A $\beta$  42) values (cut-off point chosen as 0.52). Novel CSF biomarkers included Neurofilament light (NFL), YKL-40, S100 calcium-binding protein B (S100B) and Glial fibrillary acidic protein (GFAP), measured with enzyme-linked immunosorbent assay (ELISA). Subjects underwent a neuropsychological assessment for evaluation of different cognitive domains including verbal episodic memory, non-verbal memory, language, processing speed and executive functions. **Results** Accuracy for distinguishing between the two CSF profiles was calculated for each CSF marker and cognitive domain. Verbal episodic memory performed the best overall (Area under curve [AUC]=0.80), with AUCs for CSF markers ranging from 0.61 to 0.64. For estimation of the relationships between CSF markers and cognitive domains (adjusted for age and education), Pearson's correlation and ridge regression analyses were performed. The ratio between NFL and YKL-40 levels correlated higher with verbal episodic memory score ( $r=-0.51$ ,  $p < 0.001$ ) compared to single protein levels (NFL:  $r=-0.26$ ,  $p = 0.06$ ; YKL-40:  $r=0.18$ ,  $p = 0.20$ ). The correlation was also higher among those with CSF AD profile ( $r=-0.67$ ,  $p < 0.001$ ) compared to those without ( $r=-0.46$ ,  $p = 0.03$ ). GFAP levels showed weak correlation with executive functions scores ( $r=-0.37$ ,  $p = 0.007$ ). Among those with a CSF AD profile, both S100B ( $r=-0.45$ ,  $p = 0.02$ ) and GFAP ( $r=0.68$ ,  $p < 0.001$ ) levels correlated with processing speed scores. **Conclusions** The novel CSF markers NFL, YKL-40 and GFAP show potential as markers for cognitive decline among individuals with core AD pathology at the symptomatic pre- and early stages of dementia.

## Introduction

In recent years, a paradigm shift in the research criteria of Alzheimer's disease (AD) has occurred as the primary focus has shifted from clinical to biological criteria. The emphasis is now on the pathology [1], which is believed to start decades before the appearance of clinical symptoms [2]. The core cerebrospinal fluid (CSF) biomarkers reflecting the hallmarks of AD pathology, extracellular amyloid plaques (A $\beta$ ), and neurodegeneration (total tau [T-tau] and phosphorylated tau [P-tau]) have been at the center of this shift and have been extensively studied [3]. Although the diagnostic accuracies of these markers are generally satisfactory [4], their levels are relatively constant in the symptomatic stages of the disease and do not correlate well with the progression of cognitive decline [5-7]. This necessitates the need for exploration of novel biomarkers that help in better understanding the different aspects of AD pathology, its progression, and clinical manifestation.

Increasing evidence shows that inflammation is a contributing factor in the pathogenesis and development of AD and other neurodegenerative diseases [8, 9]. A number of studies show that A $\beta$  toxicity and plaques induce an immune response, including activation of astrocytes and microglia, the immune cells of the brain [10-12]. Furthermore, activation of these cells is also thought to play a role in the formation and progression of neurofibrillary tangles (NFTs), contributing to neuronal dysfunction and loss [13]. Glial activation markers are, therefore, of high interest when it comes to exploring new biomarkers for the diagnosis of dementia.

The glial proteins YKL-40 (also known as chitinase-3-like-1 protein), calcium-binding protein S100B, and glial fibrillary acidic protein (GFAP) have previously been associated with AD pathology [14]. All are expressed in astrocytes within the central nervous system (CNS), primarily (YKL-40 and S100B) [15, 16] or exclusively (GFAP) [17]. YKL-40, a chitin-binding glycoprotein and a glial activation marker [18], has been identified inside reactive astrocytes in close proximity to amyloid plaques [19]. YKL-40 expression also correlates with tau pathology in AD brain tissues, demonstrating an association between glial activation and neurodegeneration [20]. S100B is a calcium-binding protein, exerting both intracellular and extracellular functions and has been found to be up-regulated in AD tissues [21, 22]. GFAP is a key intermediate filament protein and marker of reactive astrocytes, whose expression has been associated with amyloid plaque load and, to a lesser extent, the number of NFTs [23-25].

Inflammation in the brain and its role in AD can be studied indirectly through the analysis of CSF proteins. Increased levels of CSF YKL-40, S100B and GFAP, have been observed in AD patients compared to healthy controls, although results have not been consistent [26]. The relationship between inflammatory and core AD markers (A $\beta$ , tau) in CSF has also been explored. Previous studies have found a strong positive association between CSF YKL-40 and tau proteins but not between YKL-40 and A $\beta$ <sub>42</sub> [19, 27-29]. YKL-40 has also been shown to strongly correlate with neuronal degeneration marker neurofilament light (NFL) in CSF [30], further supporting the association between glial activation and neurodegeneration. NFL is mainly located in myelinated axons. Therefore its levels also reflect white matter changes, with recent studies indicating a potential for this protein as both a diagnostic and progression marker in AD and other neurodegenerative diseases [26, 31]. Few studies have examined the relationship between S100B and GFAP with core AD markers in CSF. Hov et al. [32] found an association between S100B and P-tau but not A $\beta$ <sub>42</sub> among elective surgery patients free from dementia and delirium. Ishiki et al. [33] did not find an association between CSF GFAP and core markers within a dementia cohort.

Loss of memory is typically among the first clinical symptoms of AD, marking the beginning of cognitive decline. The medial temporal lobe is an early site of tau accumulation, and its dysfunction may underlie episodic memory decline [34]. Other cognitive domains are also involved in AD, such as language, non-verbal episodic memory and executive functions [35].

In the most recent research criteria from the International Working Group for the diagnosis of AD published in 2014 [36], the diagnosis of prodromal AD requires both the presence of cognitive symptoms and AD signature biomarker profile (increased amyloid positron emission tomography [PET] deposition or

the combination of lowered CSF amyloid- $\beta_{1-42}$  and elevated CSF tau). It is essential for the evaluation of novel biomarkers to examine their relationship with both entities separately, independent of diagnosis. That type of approach could both enhance understanding of the underlying pathology of AD and the sequence of events leading to cognitive impairment. The first aim of this study was to assess the ability of glial (YKL-40, S100B, GFAP) and neurodegeneration (NFL) markers in CSF to discriminate between different CSF profiles (AD and non-AD) among subjects at the symptomatic pre- and early stages of dementia. In addition, the results were compared to the discrimination ability of neuropsychological tests, which are commonly used to aid AD diagnosis. The second aim was to investigate the relationship between the CSF markers with neuropsychological tests reflecting different cognitive domains.

## Methods

### Subjects

Individuals referred to The National University Hospital of Iceland Memory Clinic during a four year period which 1) had a score between 24-30 on the Mini-Mental State Examination (MMSE) and 2) a

score of 4.0 or less on the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) [37], were invited to join a prospective study on mild cognitive impairment (MCI, n=218). The exclusion criteria were 1) cognitive impairment that, without a doubt, could be explained by a condition other than dementia, 2) difficulties participating due to health or social issues, and 3) residency outside the Reykjavík Capital Area. **In entering the study, each subject underwent various assessments, including a standard clinical and neuropsychological assessment and brain magnetic resonance imaging (MRI) for evaluation of medial temporal lobe atrophy (MTA) score. Lumbar puncture for collection of CSF, which was optional by the requirement of the National Bioethics Committee, was also carried out.** For this particular study (Fig. 1), only subjects with CSF samples and complete neuropsychological assessment were selected from the cohort (n=56). The final sample included 52 subjects as four were removed due to excessively high value on CSF GFAP (n=1) or blood-contamination in the CSF sample (n=3). Clinical diagnosis of AD was based on the criteria for probable AD dementia defined by the National Institute on Aging-Alzheimer's Association (NIA-AA) [38], with evidence of AD pathophysiological processes (based on MTA score or/and analysis of core CSF markers). Patients with Lewy body dementia were diagnosed based on the consensus criteria of McKeith [39]. MCI diagnosis required the fulfillment of the Winblad criteria [40], with those not fulfilling the criteria diagnosed as having subjective mild cognitive impairment (SCI).

**Fig. 1** Flow diagram of sample selection

## CSF collection and analysis

CSF was collected via lumbar puncture with a 22-gauge spinal needle at the L3/4 or L4/5 interspace. Uncentrifuged samples were frozen in 2 ml polypropylene tubes and stored at -80 °C. Commercially available sandwich enzyme-linked immunosorbent assays (ELISAs) were used for measurements of all proteins. Analyses of established AD markers T-tau (IBL International, Hamburg, Germany) and A $\beta$ <sub>42</sub> (IBL International, Hamburg, Germany) were carried out in the ISO 15189 accredited medical laboratory MVZ Labor P.D. Dr. Volkmann und Kollegen GbR (Karlsruhe, Germany). Assays for novel markers NFL (Uman Diagnostics, Umeå, Sweden), YKL-40 (Quantikine ELISA Human Chitinase-3-like 1; R&D systems, M.N., USA), S100B (BioVendor GmbH, Heidelberg, Germany) and GFAP (BioVendor GmbH, Heidelberg, Germany) were performed in technical duplicates and according to manufacturer's instructions in a laboratory at the University of Iceland. The mean Intra-assay CV was <10% and mean Inter-assay CV <15% for all assays.

## Subject grouping based on CSF measures

Each subject was classified independently of clinical diagnosis on the basis of CSF T-tau and A $\beta$ <sub>42</sub> values. T-tau/A $\beta$ <sub>42</sub> ratio cut-off of 0.52 was chosen based on results from a large memory clinic cohort study [41], giving a sensitivity of 93% for AD and specificity of 83% for controls. A positive CSF AD profile was defined as T-tau/A $\beta$ <sub>42</sub> ratio > 0.52. The same ratio was also used as a part of the clinical diagnosis of AD, explaining full concordance with CSF AD profile.

## Neuropsychological tests

All subjects underwent a detailed neuropsychological assessment performed by licensed psychologists. Five cognitive domains, commonly affected by aging and AD, were assessed using seven tests (Table 1). For the evaluation of verbal episodic memory, two tests were used. The first, Rey Auditory Verbal Learning Test (RAVLT), consisted of 15 nouns read aloud by the examiner for five consecutive trials. Each trial was followed by a free-recall test. After a 30 minute delay, subjects were required to recall the words without being reread the list [42]. The second test was composed of a story [43], which included 25 ideas verbally presented by the examiner. Right after the story was presented (immediate recall), the subject was asked to repeat what they remembered without being given any clues (free recall). Thirty minutes later, subjects were asked to recall the story again (delayed recall). The Rey–Osterrieth complex figure test (ROCF) was used to assess non-verbal episodic memory [42]. The subject was asked to reproduce a complicated line drawing, first by copying it free-hand, second by drawing from memory (immediate recall) and third by drawing it after a 30-minute delay (delay recall). Verbal fluency [44] was evaluated with subjects having to produce as many animals names and words starting with the letters H and S as possible in 60

seconds. Two subtests were used to evaluate processing speed. Part A of The Trail Making Test (TMT-A) [45] required subjects to connect 25 numbered circles positioned randomly on a piece of paper. The first and the most simple part of the Stroop test - Word reading - was also used for the evaluation of the same cognitive domain [46]. Subjects were shown a list of color names (red, green, yellow or blue), each printed in black ink, and told to read out loud as rapidly as possible. For evaluation of executive functions, The Digit Symbol Substitution Test (DSST), Trail making Test B (TMT-B) and Stroop 4<sup>th</sup>/3<sup>rd</sup> parts were used. DSST [47] is a paper-and-pencil test that requires the participant to match symbols to numbers according to a key located at the top of the page. The subject copied the symbol into spaces below a row of numbers. The number of correct symbols within 120 seconds, constituted the score. TMT-B includes both numbers (1-13) and letters (A-L), with the subject drawing lines between circles, alternating between numbers and letters (1-A-2-B-3-C, etc.). In Stroop - part 4, subjects had to name the color of words when color and meaning were incongruent. Part 3 – naming of squares of given colors – were used to control for speed by calculating the ratio between the two parts.

**Table 1** List of neuropsychological tests administrated

Cognitive domain	Neuropsychological test	Scores (range)
Verbal episodic memory	RAVLT immediate recall	Free recall - the sum of the number of words recalled from trials 1 through 5 (0 to 75)
	RAVLT delayed recall	Delayed free recall – number of words recalled after 30 minutes delay (0 to 15)
	RAVLT recognition – false positives	Recognition - number of words recognized from a list of 45 words. Number of false positives subtracted from the score (-30 to 15)
	Story immediate recall	Recall of a story containing 25 ideas (0 to 25)
	Story delayed recall	Recall of a story containing 25 ideas again after 30 minutes delay (0 to 25)
Non-verbal episodic memory	ROCF immediate recall	Complicated drawing reproduced (0 to 36)
	ROCF delayed recall	Complicated drawing reproduced again after 30 minutes delay (0 to 36)
Language	Verbal fluency animals	Number of animal names produced in 60 seconds
	Verbal fluency H+S	Number of words that begin with H/S in 60 seconds
Processing speed	TMT-A	Time in seconds to connect a set of 25 numbered dots in sequential order
	Stroop test, part I	Time in seconds to read a set of color words written in black
Executive functions	DSST	Number of symbols correctly produced in 120 seconds
	TMT-B	Time in seconds to connect 25 targets, alternating between numbers and letters
	Stroop 4 <sup>th</sup> /3 <sup>rd</sup> part	Part 3 – Time in seconds it takes to name squares of given colors Part 4 – Time in seconds it takes to name the color of a word

Abbreviations: *RAVLT* Rey Auditory Verbal Learning Test, *ROCF* Rey–Osterrieth complex figure, *DSST* Digit symbol substitution test, *TMT* Trail Making Test

## Statistical analysis

Descriptive group comparisons were performed using Mann-Whitney U tests and chi-square tests for continuous and categorical variables, respectively. Raw values of CSF measures and selected neuropsychological tests (TMT, Stroop test, DSST) were naturally log-transformed to account for a non-normal distribution. Composite scores for each cognitive domain were calculated by averaging

neuropsychological test z-scores and subsequently converting those scores into z-scores. Before the computation of composite scores, z-scores for tests measuring reaction time were reversed (TMT, Stroop test, DSST) for the purpose of test consistency (higher scores always indicating better performance). Receiver operating characteristic (ROC) curves were constructed for the differentiation between CSF AD and non-AD profiles. The discrimination abilities of each CSF marker and cognitive domain were compared using the area under the curve (AUC) method, according to DeLong et al. [48]. The AUC is the probability that a randomly selected pair of subjects from each CSF profile group is correctly classified. Stability selection was employed in combination with Least Absolute Shrinkage and Selection Operator (LASSO) regression for the purpose of identifying stable predictors in multivariable models [49]. LASSO is a penalized approach to multiple regression and especially useful when dealing with multicollinearity (highly correlated predictors). A penalty is introduced, reducing large variance due to multicollinearity in exchange for a tolerable amount of bias. It also performs variable selection as it imposes coefficients of some variables to shrink towards *zero*. Stable selection is based on resampling the data for avoidance of overfitting, which can be advantageous when dealing with smaller data sets. Instead of fitting one model on a whole sample, many models are fitted on subsamples drawn from it. Stability selection was performed by the use of the function `stabsel` in the package `stabs`, implementing the package `glmnet` for LASSO model fitting [50, 51]. Cut-off value for stable selection was set to 75% (the percentage of times a variable was selected into a model) and per-family error rate (PFER) to 1 for all analyses. Each subsample was half the size of the original one, with 100 subsamples being drawn. LASSO logistic regression was applied for the selection of novel CSF markers and composite tests, most accurately distinguishing between the two CSF profiles. LASSO linear regression was used to select variables, out CSF markers and demographic variables, predicting with most accuracy the composite z-score for each cognitive domain. Two LASSO regressions with a stability selection were performed for each cognitive domain, one which included all subjects and the other, which only included those with a CSF AD profile. Scatter plots were used for visualization of the selected relationships between CSF markers and cognitive domains. Cognitive domain measures were adjusted for age and education before the calculations of corresponding Pearson's correlations coefficients. For the adjustment, linear regression models were created with each composite test z-score as the dependent variable and age and education as independent variables. The residual for each subject was subsequently calculated (observed minus predicted score). Significance values were not adjusted for multiple comparisons, as this study was viewed as explorative with emphasis on discovering relationships. All statistical analyses were performed using R (version 3.6.1, The R Foundation for Statistical Computing).

## Results

### Sample characteristics

Table 2 shows the demographic, pathophysiological and clinical characteristics of the cohort by CSF profile. There were no significant differences between the groups in age, length of education, novel CSF protein levels or gender frequencies. Boxplots comparing distributions in CSF protein levels (NFL, YKL-40, S100B, GFAP) between profile groups are presented in Additional file 1, S1a-d. The CSF AD profile group

showed significantly worse performance on the MMSE, RAVLT, Story, ROCF immediate recall and Verbal fluency animal tests compared to the non-AD group ( $p < 0.05$ ).

**Table 2** Subject demographics, CSF marker levels and neuropsychological test scores by CSF profile

	CSF profile		<i>p</i> value $\square$
	Non-AD T-tau/ A $\beta$ <sub>42</sub> $\leq$ 0.52 (n=24)	AD T-tau/ A $\beta$ <sub>42</sub> > 0.52 (n=28)	
<i>Demographics</i>			
Gender (M/F)	16/8	17/11	0.66
Age, years	67 (46-80)	70 (51-84)	0.17
Education, years	14.0 (9-20)	12.5 (6-17)	0.11
<i>Clinical diagnosis</i>			
SCI/MCI/AD/LBD	10/13/0/1	2/9/16/1	N/A <sup>b</sup>
<i>CSF measures</i>			
A $\beta$ <sub>42</sub> (pg/ml)	703 (374-2332)	454 (160-822)	N/A <sup>c</sup>
T-tau (pg/ml)	173 (100-722)	416 (132-838)	N/A <sup>c</sup>
NFL (ng/ml)	1.9 (0.9-6.5)	2.5 (1.2-4.5)	0.15
YKL-40 (ng/ml)	165 (83-399)	203 (124-367)	0.12
S100B (pg/ml)	215 (132-335)	230 (129-458)	0.17
GFAP (ng/ml)	1.0 (0.1-7.1)	1.3 (0.5-21.3)	0.09
<i>Cognitive domains</i>			
<i>Global cognition</i>			
MMSE, score	28 (24-30)	27 (24-30)	0.01
<i>Verbal episodic memory</i>			
RAVLT immediate recall, score	36 (23-66)	26.5 (13-51)	0.003
RAVLT delayed recall, score	6.5 (0-15)	1.5 (0-12)	<0.001
RAVLT recognition-fp, score	9.0 (3-15)	5.5 (-3-15)	0.003
Story immediate recall, score	13.5 (5-17)	8 (1-18)	0.005
Story delayed recall, score	12.0 (1-19)	5.5 (0-16)	0.002
<i>Non-verbal episodic memory</i>			
ROCF immediate recall, score	13.3 (0-27)	7.3 (0-26)	0.04
ROCF delayed recall, score	12.8 (0-25)	8.5 (0-26)	0.07
<i>Language</i>			
Verbal fluency animal, score	20 (8-33)	14 (4-27)	0.02
Verbal fluency H+S, score	24.0 (14-48)	25.5 (6-63)	1.00
<i>Processing speed</i>			
TMT-A, sec.	43.5 (21-133)	48.0 (27-116)	0.22
Stroop – part I, sec.	23.5 (20-42)	24.5 (17-34)	0.64
<i>Executive functions</i>			
TMT-B, sec.	109 (44-340)	153 (60-343)	0.06
DSST, score	8.5 (3-51)	7.0 (2-61)	0.24
Stroop 4 <sup>th</sup> /3 <sup>rd</sup> part, sec.	2.1 (1.4-4.0)	2.1 (1.6-5.8)	0.25

Abbreviations: *AD* Alzheimer's disease, *CSF* Cerebrospinal fluid, *DDST* Digit symbol substitution test, *fp* false positives, *LBD* Lewy body dementia, *MCI* Mild Cognitive Impairment, *MMSE* Mini-Mental State – Examination, *N/A* Not applicable, *RAVLT* Rey Auditory-Verbal Learning Test, *ROCF* Rey–Osterrieth complex figure, *SCI* Subjective Cognitive Impairment, *TMT* Trail Making Test

Values are shown as median (range) or as numbers per group, <sup>‡</sup>Mann-Whitney U non-parametric tests used for continuous variables and Chi-Square tests for categorical variables, *p*-values not applicable for <sup>b</sup>clinical diagnosis due to CSF profiles being part of the diagnostic criteria for AD and

<sup>c</sup>A $\beta_{42}$  and T-tau due to their values used for defining CSF profiles

### Pearson's correlations between CSF markers

Pearson's correlations between the CSF markers, age and length of education are presented in Fig. 2, respectively. Inflammatory markers YKL-40 and S100B and neurodegeneration markers NFL and T-tau all correlated positively and significantly with each other. The highest correlation was found between NFL and YKL-40 (NFL:  $r=0.62$ ,  $p<0.001$ ). GFAP did only significantly correlate with the CSF marker S100B ( $r=0.53$ ,  $p<0.001$ ). No CSF markers correlated significantly with A $\beta_{42}$ . All the CSF markers, except for A $\beta_{42}$ , correlated positively with age. Length of education correlated weakly and negatively with T-tau ( $r=-0.29$ ,  $p=0.03$ ).

**Fig. 2** Pearson's correlation matrix between CSF markers, age and length of education. Colored squares indicate statistical significance ( $p<0.05$ ). CSF measures were natural log-transformed

### Accuracy of CSF markers and cognitive domains in distinguishing between CSF profiles

Accuracies for distinguishing between CSF AD and non-AD profiles were based on univariable ROC analyses (Table 3). AUCs for novel CSF markers ranged from 0.61 - 0.64, with a lower limit of each confidence interval below the value of 0.5. In comparison, neuropsychological tests reflecting verbal episodic memory had the highest accuracy compared to other measurements, with all AUCs over 0.70, which is considered fair [52]. The scores for the Verbal episodic memory composite test (AUC=0.80, CI: 0.69-0.92) and RAVLT delayed recall (AUC=0.80, CI: 0.68-0.93) distinguished the best between the CSF profile groups. A similar trend in results was found when ROC analyses were stratified by gender (Table S1, Additional file 1), although AUC coefficients were overall higher for women ( $n=19$ ) compared to men ( $n=33$ ). LASSO logistic regression with stability selection was performed for the selection of variables distinguishing between the CSF profile groups with the highest consistency. Nine possible predictors could be selected, the four novel CSF markers and the five composite tests presenting each cognitive domain. Only the test reflecting verbal episodic memory was selected as a predictor, with selection frequency (96%) above the cut-off value. All other possible predictors had a much lower selection frequency ( $\leq 20\%$ ).

**Table 3** Accuracy in distinguishing between CSF AD and non-AD profiles

	Univariable ROC analyses		Multivariable LASSO logistic regression <sup>b</sup>
	AUC	95% CI (AUC)*	Stability selection (%)
<i>CSF measures</i>			
GFAP (ng/ml)	0.64	0.48-0.79	10
YKL-40 (ng/ml)	0.63	0.47-0.78	18
NFL (ng/ml)	0.62	0.45-0.78	2
S100B (pg/ml)	0.61	0.46-0.77	20
<i>Cognitive domains</i>			
<i>Verbal episodic memory</i>			
Composite z-score	0.80	0.69-0.92	96 <sup>c</sup>
RAVLT delayed recall, score	0.80	0.68-0.93	-
Story delayed recall, score	0.75	0.62-0.89	-
RAVLT immediate recall, score	0.74	0.61-0.88	-
RAVLT recognition-fp, score	0.74	0.61-0.87	-
Story immediate recall, score	0.73	0.59-0.86	-
<i>Non-verbal episodic memory</i>			
Composite z-score	0.65	0.50-0.81	14
ROCF immediate recall, score	0.66	0.51-0.81	-
ROCF delayed recall, score	0.65	0.49-0.80	-
<i>Executive functions</i>			
Composite z-score	0.64	0.49-0.80	16
TMT-B, sec. $\square$	0.66	0.50-0.81	-
DSST, score $\square$	0.60	0.44-0.75	-
Stroop 4 <sup>th</sup> /3 <sup>rd</sup> part, sec. $\square$	0.59	0.43-0.75	-
<i>Language</i>			
Composite z-score	0.60	0.44-0.76	4
Verbal fluency animals, score	0.68	0.54-0.83	-
Verbal fluency H+S, score	0.50	0.34-0.66	-
<i>Processing speed</i>			
Composite z-score	0.56	0.39-0.72	9
TMT-A, sec. $\square$	0.60	0.44-0.76	-
Stroop test – part I, sec. $\square$	0.54	0.38-0.70	-

*Abbreviations:* AD Alzheimer's disease, AUC Area under curve, CI Confidence Intervals, CSF Cerebrospinal fluid, DDST Digit symbol substitution test, fp false positives, LASSO Least absolute shrinkage and selection operator, RAVLT Rey Auditory-Verbal Learning Test, ROCF Rey-Osterrieth complex figure, TMT Trail Making Test

AUC is the probability that a randomly selected pair of subjects from each CSF profile group is correctly classified, \*Confidence intervals calculated with DeLong method,  $\square$  Values are natural log-transformed, <sup>b</sup>LASSO logistic regression model was fitted on 100 subsamples, with different predictors (CSF measures and composite test scores) possibly selected into each model. Numbers present the frequency (%) of each possible predictor selected. The per-family error rate (PFER) was set at 1, and the cut-off value at 75% for stability selection. <sup>c</sup>The composite test for verbal episodic memory was the only measure to have selection frequency above the cut-off value

Fig. 3 illustrates the ROC curves for the two cognitive domains and the CSF measure with the highest AUC from Table 3. Verbal episodic memory (AUC=0.80) was superior in distinguishing between CSF AD vs. non-AD profiles compared to non-verbal episodic memory (AUC=0.65) and CSF GFAP (0.64).

**Fig. 3** Comparison between ROC curves of the two cognitive domains and the CSF marker with the highest area under the curve (AUC) coefficients

#### Selection of predictors for scores on each cognitive domain

LASSO linear regression with a stability selection was applied for identifying a set of variables (CSF markers and demographic variables) predicting cognitive scores with the highest consistency (Fig. 4). Two analyses were performed for each of the five domains, one including all subjects (n=52) and the other only among those with a CSF AD profile (n=28). Variables with stability selection above 75%, were considered reliable predictors. GFAP (78%) was selected as a predictor for executive functions (Fig. 4a) and age (95%) as a predictor for non-verbal memory (Fig. 4b) within the whole cohort. Among subjects with a CSF AD profile, GFAP (87%) and age (81%) were selected as predictors for processing speed (Fig. 4c) and NFL (80%) for verbal episodic memory (Fig. 4d). No variables reached the stability selection criteria as predictors of scores reflecting language (Fig. 4e).

**Fig. 4.** LASSO linear regression - stability selection analyses for prediction of composite z-scores reflecting a) verbal episodic memory, b) non-verbal episodic memory, c) language, d) processing speed and e) executive functions. Two analyses were created for each domain, one including all participants (n=52) and the other only the CSF AD profile group (n=28). The cut-off selection value was set at 75% and the per-family error rate (PFER) at 1 for all analyses.

#### Pearson's correlations between selected CSF markers and cognitive domains

Relationships between CSF measures and cognitive domains, as selected with LASSO regression – stability selection analyses (Fig. 4), were visualized using scatter plots. It is well established that normal aging, level and quality of education can influence cognitive test performance [53]. Composite z-scores were therefore adjusted for age and education prior to Pearson's correlations calculations.

CSF NFL levels did not significantly correlate with verbal episodic memory among all subjects ( $r=-0.26$ ,  $p=0.06$ , Fig. 5a). Analysis by CSF profile (Fig. 5b) revealed moderate, significant correlation among subjects with a CSF AD profile ( $r=-0.43$ ,  $p=0.02$ ) compared to none among those without ( $r=-0.05$ ,  $p=0.82$ ).

Correlations between the NFL levels and individual neuropsychological tests reflecting verbal episodic memory are presented in Additional file 1, S2a-e. T-tau did not reach the selection criteria for any cognitive domain. It is, none the less, of interest to compare the results of T-tau to NFL as both proteins are markers of neurodegeneration. The association between T-tau and verbal episodic memory was similar to NFL within the whole cohort ( $r=-0.28$ ,  $p<0.04$ , Fig. 5c) but did not reach significance within the CSF AD group ( $r=-0.15$ ,  $p=0.45$ ) when analyzed by CSF profile (Fig. 5d).

Correlation between CSF GFAP levels and processing speed did not reach significance within the whole cohort ( $r=-0.27$ ,  $p=0.06$ , Fig. 5e) or among those with a CSF non-AD profile ( $r=0.02$ ,  $p=0.94$ , Fig. 5f). A moderately strong correlation was, on the other hand, detected among those with a CSF AD profile ( $r=-0.68$ ,  $p<0.001$ , Fig. 5f). A weak, negative correlation was found between CSF GFAP levels and executive functions, both within the whole cohort ( $r=-0.37$ ,  $p=0.01$ , Fig. 5g) and among subjects with a CSF AD profile ( $r=-0.39$ ,  $p=0.04$ , Fig. 5h). The corresponding correlations between CSF GFAP levels with individual neuropsychological tests reflecting processing speed and executive functions are presented in Additional file 1, Fig. S3a-e. Additional file 1 also includes scatter plots identical to those shown in figure 5 without adjustment for age and education (Fig. S4a-h) and Pearson's correlations between CSF markers, age and education and composite scores of each cognitive domain, both unadjusted and adjusted for age and education (Table S2).

**Fig. 5.** Scatter plots presenting Pearson's correlations between CSF levels of NFL and verbal episodic memory (a,b), T-tau and verbal episodic memory (c,d), GFAP and processing speed (e,f) and GFAP and executive functions (g,h) within the whole cohort and by CSF profile. \*Cognitive domains were adjusted for covariates (age and education). Without the bottom corner GFAP outlier in the CSF AD profile group, Pearson's correlations were a slightly lower for f) processing speed ( $r=-0.58$ ,  $p=0.001$ ) and h) executive functions ( $r=-0.28$ ,  $p=0.15$ )

## Discussion

We compared different CSF biomarkers reflecting neurodegeneration (NFL) and inflammation (YKL-40, S100B and GFAP) in relation to core CSF AD markers and cognitive functions in a cohort of subjects at the pre- and early symptomatic dementia stages. While our results indicated that these CSF markers did not improve the accuracy of distinguishing between AD and non-AD CSF profiles, they exhibited different patterns of association with certain cognitive domains, as evaluated by various neuropsychological tests. This pattern was mainly observed among subjects with a CSF AD profile. Within that group, levels of the neurodegeneration marker NFL associated with verbal episodic memory while inflammatory marker GFAP associated with processing speed. In addition, GFAP associated weakly with executive functions within the whole cohort. Overall, these results indicate that CSF NFL and GFAP levels do relate to cognitive functions, specifically among those with a CSF AD profile.

Both CSF NFL and YKL-40 levels correlated with T-tau but not with  $A\beta_{42}$ , in accordance with previous studies [54-56], thereby NFL and YKL-40 levels most likely reflect processes that are independent of  $A\beta$  pathology [57-59]. The putative inflammatory marker, S100B, did show a similar trend as YKL-40 within the whole cohort, correlating strongly with CSF neurodegeneration markers (NFL and T-tau) but not with  $A\beta_{42}$  levels. In contrast, GFAP did not correlate with the CSF neurodegeneration markers nor with CSF  $A\beta_{42}$  levels. Neither CSF S100B nor GFAP have been much studied in terms of correlation with CSF core AD markers. Hov et al. [32] found similar results among elective surgery patients free from dementia and delirium, with S100B positively correlating with P-tau but not with  $A\beta_{42}$  in CSF. Ishiki et al. [33] did not find an association between GFAP and the core AD markers within a sample of healthy subjects and dementia patients. Here we found that CSF NFL, YKL-40, S100B and GFAP, all performed poorly in differentiating between the CSF AD and non-AD profiles. In summary, these results are in accordance with previous findings that have suggested markers NFL, YKL-40, S100B and GFAP to be not AD specific.

The neuropsychological tests reflecting verbal episodic memory did show the best accuracy in differentiating between the CSF profiles out of all the evaluated cognitive measures and the novel CSF markers. The accuracy was good for the composite score of verbal episodic memory and RAVLT delayed recall test (80%), but fair for all the other verbal episodic memory tests (between 70-80%). A recent meta-analysis [60] based on 47 studies has shown that immediate and delayed memory tests consistently show good accuracy (above 80%) for differentiating between AD and healthy controls, especially those involving list recall. Importantly, these studies are based on the clinical diagnosis of AD, while our focus was on the signature of the CSF AD biomarker profile.

CSF markers related in different ways to cognitive measures. Both CSF NFL [56, 61] and YKL-40 [59] have been previously reported to associate with cognitive decline, with correlation found between CSF levels and global cognition assessed by MMSE test scores among AD patients. In the same studies, the correlation did not hold for patients with MCI. Thus, NFL and YKL-40 might not be sensitive to very early changes in cognition in the earliest symptomatic stages of dementia (SCI, MCI) as in more advanced stages. In this study, the relationship between NFL and YKL-40 with different cognitive domains within the whole cohort could not be confirmed. A possible explanation could be that a majority of subjects (n=34) were at the SCI or MCI stages, with 23 of those without a CSF AD profile.

Knowledge regarding the relationship between core CSF biomarkers and cognition remains incomplete. Overall,  $A\beta_{42}$  and T-tau appear to associate with memory and executive functions in some studies [62, 63], although results have not been consistent in terms of which cognitive domains they are associated with, which particular tests are most suitable and the strength of relationships in different clinical stages [62, 64, 65]. However, the levels of core CSF marker have shown evidence of reaching a plateau early in the clinical course of the disease and are therefore not considered ideal for tracking the progression of disease at later stages [66].

Increased CSF levels of inflammatory marker GFAP was found weakly associated with worse performance on tests reflecting executive functions, both within the whole cohort and among subjects

with CSF AD profile. Few studies have examined the relationship between CSF GFAP levels and cognitive functions. Ishiki et al. [33] did not find an association between CSF GFAP levels and MMSE scores in a sample of healthy subjects and dementia patients. Darreh-Shori et al. [67] also reported no correlation between CSF GFAP levels and MMSE scores among AD patients. As with CSF GFAP, little research has been conducted on the association between CSF S100B levels and cognition. In the same study [67] a weak, positive relationship was found between levels of CSF S100B and MMSE scores within the same patient group.

Associations between selected CSF markers and cognitive domains were also examined within each CSF profile. CSF NFL levels moderately related to verbal episodic memory among those with CSF AD profile but not among those without. Higher levels of CSF GFAP also moderately associated with worse performance on processing speed only within the CSF AD profile group. This is of interest because the CSF markers did not directly relate to the CSF AD profile (ability in discriminating between CSF profiles was poor). This outcome could possibly be explained by the additive effects of distinctive processes on cognitive functions. A previous study [68] showed a similar trend where CSF YKL-40 levels associated with less preservation of global cognition only in individuals with low A $\beta$  levels (A $\beta$  positive). CSF A $\beta$  levels did though not correlate with YKL-40 or cognitive decline, but to brain atrophy in A $\beta$  positive subjects.

This study has several limitations. First, the sample was relatively small, and hence present findings need to be validated in a larger study. The sample did not include healthy controls, which could underestimate associations between the studied variables. Another *limitation* of the study is the lack of information about the ApoE genotype. However, it is unlikely that the ApoE genotype affects the outcome as previous studies have suggested that ApoE  $\epsilon$ 4 status does not influence CSF NFL or YKL-40 levels [19, 69, 70].

## Conclusions

Our findings suggest that levels of CSF markers NFL and GFAP relate to different cognitive profiles at the symptomatic pre- and early dementia stages. The relationships between the levels of NFL with verbal episodic memory and GFAP with processing speed were only observed among those with CSF AD profile, although the CSF markers did not directly relate to the CSF AD profile. These CSF markers could be of potential use as progression markers, monitoring subtle cognitive changes at the earliest symptomatic stages of dementia among those with AD pathology. Further studies with bigger group sizes are needed to validate these results and to evaluate their potential in tracking changes in the more advanced stages of AD and other types of dementia.

## Additional File

**Additional file 1: Figure 1.** Levels of CSF NFL, YKL-40, S100B and GFAP by CSF profile. **Table 1.** Univariable ROC analysis for distinguishing between CSF profile groups stratified by gender. **Figure 2.** Pearson's correlations between levels of CSF NFL with neuropsychological tests reflecting verbal episodic

memory by CSF profile. **Figure 3.** Pearson's correlations between levels of CSF GFAP with neuropsychological tests reflecting processing speed and executive functions by CSF profile. **Figure 4.** Pearson's correlations between CSF levels of NFL and T-tau with verbal episodic memory and GFAP with processing speed and executive functions, within the whole cohort and by CSF profile. **Table 2.** Pearson's correlations between CSF markers, age, education and composite z-scores reflecting cognitive domains. (DOCX 1,010 kb)

## Declarations

### Acknowledgments

The authors express their sincere gratitude to all the subjects of The Icelandic MCI study. They also thank the staff of the Landspítali – University Hospital Memory Clinic, specifically Kristin H. Hannesdóttir, for managing participant administration.

### Funding

This study was funded by the St. Josef's Hospital Fund, Reykjavik, Iceland, the Landspítali University Hospital Research Fund and the Icelandic Research Fund of the Icelandic Centre for Research (163172-051).

### Availability of data and materials

The data which support this study are not publicly available, but may be provided upon reasonable request.

### Authors' contributions

UDT, J.S. and PHP contributed to the conception and design of the study. UDT and MKJ contributed to the collection of data. UDT performed the statistical analysis and drafted the manuscript. SHL provided guidance on statistical analysis and verified the results. PHP, J.S., T.D., SHL and MJK revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

### Ethics approval and consent to participate

The study has been approved by the National Research Ethics Committee of Iceland (VSN-14-028), and all subjects signed an informed consent. The study was conducted in accordance with the Helsinki

Declaration latest revision of 2013.

### **Consent for publication**

Not applicable.

### **Competing interests**

The authors declare that they have no competing interests.

## **Abbreviations**

AD: Alzheimer's disease

AUC: Area under curve

A $\beta$ <sub>42</sub>: Amyloid- $\beta$ <sub>1-42</sub>

CSF: Cerebrospinal fluid

DSST: Digit Symbol Substitution Test

F.P.: False positives

GFAP: Glial fibrillary acidic protein

IQCODE: Informant Questionnaire on Cognitive Decline in the Elderly

LASSO: Least absolute shrinkage and selection operator

LBD: Lewy body dementia

MCI: Mild cognitive impairment

MMSE: Mini-mental state examination

MTA: Medial temporal lobe atrophy

NFL: Neurofilament light

NFTs: Neurofibrillary tangles

PET: Positron emission tomography

PFER: Per-family error rate

P-tau: Phosphorylated tau

RAVLT: Rey Auditory Verbal Learning Test

ROC: Receiver operating characteristic

ROCF: Rey–Osterrieth Complex Figure

S100B: S100 calcium-binding protein B

SCI: Subjective cognitive impairment

TMT: Trail Making Test

T-tau: Total-tau

## References

1. Jack, C.R., Jr., et al., *NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease*. *Alzheimers Dement*, 2018. **14**(4): p. 535-562.
2. Bateman, R.J., et al., *Clinical and biomarker changes in dominantly inherited Alzheimer's disease*. *N Engl J Med*, 2012. **367**(9): p. 795-804.
3. Ittner, L.M. and J. Gotz, *Amyloid-beta and tau—a toxic pas de deux in Alzheimer's disease*. *Nat Rev Neurosci*, 2011. **12**(2): p. 65-72.
4. Ferreira, D., et al., *Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteria*. *Front Aging Neurosci*, 2014. **6**: p. 47.
5. Perrin, R.J., A.M. Fagan, and D.M. Holtzman, *Multimodal techniques for diagnosis and prognosis of Alzheimer's disease*. *Nature*, 2009. **461**(7266): p. 916-22.
6. Zhou, B., et al., *Validity of cerebrospinal fluid biomarkers as endpoints in early-phase clinical trials for Alzheimer's disease*. *J Alzheimers Dis*, 2009. **18**(1): p. 89-102.
7. Jack, C.R., Jr., et al., *Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade*. *Lancet Neurol*, 2010. **9**(1): p. 119-28.
8. Ardura-Fabregat, A., et al., *Targeting Neuroinflammation to Treat Alzheimer's Disease*. *CNS Drugs*, 2017. **31**(12): p. 1057-1082.
9. Calsolaro, V. and P. Edison, *Neuroinflammation in Alzheimer's disease: Current evidence and future directions*. *Alzheimers Dement*, 2016. **12**(6): p. 719-32.
10. Medeiros, R. and F.M. LaFerla, *Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony*. *Exp Neurol*, 2013. **239**: p. 133-8.


11. El Khoury, J.B., et al., *CD36 mediates the innate host response to beta-amyloid*. J Exp Med, 2003. **197**(12): p. 1657-66.
12. Steardo, L., Jr., et al., *Does neuroinflammation turn on the flame in Alzheimer's disease? Focus on astrocytes*. Front Neurosci, 2015. **9**: p. 259.
13. Heppner, F.L., R.M. Ransohoff, and B. Becher, *Immune attack: the role of inflammation in Alzheimer disease*. Nat Rev Neurosci, 2015. **16**(6): p. 358-72.
14. Carter, S.F., et al., *Astrocyte Biomarkers in Alzheimer's Disease*. Trends Mol Med, 2019. **25**(2): p. 77-95.
15. Bonne-Barkay, D., et al., *Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation*. Brain pathology (Zurich, Switzerland), 2012. **22**(4): p. 530-546.
16. Donato, R., et al., *S100B's double life: Intracellular regulator and extracellular signal*. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2009. **1793**(6): p. 1008-1022.
17. Yang, Z. and K.K. Wang, *Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker*. Trends Neurosci, 2015. **38**(6): p. 364-74.
18. Rehli, M., et al., *Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation*. J Biol Chem, 2003. **278**(45): p. 44058-67.
19. Craig-Schapiro, R., et al., *YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease*. Biol Psychiatry, 2010. **68**(10): p. 903-12.
20. Querol-Vilaseca, M., et al., *YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies*. J Neuroinflammation, 2017. **14**(1): p. 118.
21. Griffin, W.S., et al., *Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease*. Proc Natl Acad Sci U S A, 1989. **86**(19): p. 7611-5.
22. Mrak, R.E., J.G. Sheng, and W.S. Griffin, *Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease*. J Neuropathol Exp Neurol, 1996. **55**(3): p. 273-9.
23. Hanzel, D.K., et al., *High-throughput quantitative histological analysis of Alzheimer's disease pathology using a confocal digital microscanner*. Nat Biotechnol, 1999. **17**(1): p. 53-7.
24. Muramori, F., K. Kobayashi, and I. Nakamura, *A quantitative study of neurofibrillary tangles, senile plaques and astrocytes in the hippocampal subdivisions and entorhinal cortex in Alzheimer's disease, normal controls and non-Alzheimer neuropsychiatric diseases*. Psychiatry Clin Neurosci, 1998. **52**(6): p. 593-9.
25. Vehmas, A.K., et al., *Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease*. Neurobiol Aging, 2003. **24**(2): p. 321-31.
26. Olsson, B., et al., *CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis*. Lancet Neurol, 2016. **15**(7): p. 673-684.
27. Alcolea, D., et al., *Relationship between cortical thickness and cerebrospinal fluid YKL-40 in pre-dementia stages of Alzheimer's disease*. Neurobiology of Aging, 2015. **36**(6): p. 2018-2023.

28. Alcolea, D., et al., *Relationship between beta-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease*. J Alzheimers Dis, 2014. **42**(1): p. 157-67.
29. Antonell, A., et al., *Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease*. J Alzheimers Dis, 2014. **42**(3): p. 901-8.
30. Melah, K.E., et al., *Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease*. J Alzheimers Dis, 2016. **50**(3): p. 873-86.
31. Olsson, B., et al., *Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders*. JAMA Neurol, 2019. **76**(3): p. 318-325.
32. Hov, K.R., et al., *Cerebrospinal Fluid S100B and Alzheimer's Disease Biomarkers in Hip Fracture Patients with Delirium*. Dementia and geriatric cognitive disorders extra, 2017. **7**(3): p. 374-385.
33. Ishiki, A., et al., *Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration*. J Neurochem, 2016. **136**(2): p. 258-61.
34. Small, S.A., et al., *A pathophysiological framework of hippocampal dysfunction in ageing and disease*. Nat Rev Neurosci, 2011. **12**(10): p. 585-601.
35. Snowden, J.S., et al., *Cognitive phenotypes in Alzheimer's disease and genetic risk*. Cortex, 2007. **43**(7): p. 835-45.
36. Dubois, B., et al., *Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria*. Lancet Neurol, 2014. **13**(6): p. 614-29.
37. Jorm, A.F., *A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): development and cross-validation*. Psychol Med, 1994. **24**(1): p. 145-53.
38. McKhann, G.M., et al., *The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease*. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2011. **7**(3): p. 263-269.
39. McKeith, I.G., et al., *Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium*. Neurology, 2017. **89**(1): p. 88-100.
40. Winblad, B., et al., *Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment*. Journal of Internal Medicine, 2004. **256**(3): p. 240-246.
41. Duits, F.H., et al., *The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?* Alzheimers Dement, 2014. **10**(6): p. 713-723.e2.
42. Lezak, M.D., *Neuropsychological assessment*. 2012, Oxford: Oxford University Press.
43. Wechsler, D., *WMS-R : Wechsler Memory Scale-Revised : Manual*. 1987, San Antonio: Harcourt Brace Jovanovich.

44. Shao, Z., et al., *What do verbal fluency tasks measure? Predictors of verbal fluency performance in older adults*. *Frontiers in psychology*, 2014. **5**: p. 772-772.
45. Tombaugh, T.N., *Trail Making Test A and B: normative data stratified by age and education*. *Arch Clin Neuropsychol*, 2004. **19**(2): p. 203-14.
46. Stroop, J.R., *Studies of interference in serial verbal reactions*. *Journal of Experimental Psychology*, 1935. **18**(6): p. 643-662.
47. Wechsler, D., *Wechsler adult intelligence scale—Fourth Edition (WAIS–IV)*. San Antonio, TX: NCS Pearson, 2008. **22**: p. 498.
48. DeLong, E.R., D.M. DeLong, and D.L. Clarke-Pearson, *Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach*. *Biometrics*, 1988. **44**(3): p. 837-45.
49. Tibshirani, R., *Regression Shrinkage and Selection via the Lasso*. *Journal of the Royal Statistical Society. Series B (Methodological)*, 1996. **58**(1): p. 267-288.
50. Hofner, B., L. Boccutto, and M. Göker, *Controlling false discoveries in high-dimensional situations: boosting with stability selection*. *BMC Bioinformatics*, 2015. **16**(1): p. 144.
51. Meinshausen, N. and P. Bühlmann, *Stability selection*. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)*, 2010. **72**(4): p. 417-473.
52. *Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group*. *Neurobiol Aging*, 1998. **19**(2): p. 109-16.
53. Ganguli, M., et al., *Age and education effects and norms on a cognitive test battery from a population-based cohort: the Monongahela-Youghiogheny Healthy Aging Team*. *Aging & mental health*, 2010. **14**(1): p. 100-107.
54. Alcolea, D., et al., *Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease*. *Neurology*, 2015. **85**(7): p. 626-33.
55. Mattsson, N., et al., *Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease*. *EMBO molecular medicine*, 2016. **8**(10): p. 1184-1196.
56. Olsson, B., et al., *Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders*. *JAMA Neurol*, 2018.
57. Gangishetti, U., et al., *Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease*. *Alzheimers Res Ther*, 2018. **10**(1): p. 98.
58. Mattsson, N., et al., *Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease*. *EMBO Mol Med*, 2016. **8**(10): p. 1184-1196.
59. Kester, M.I., et al., *Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort*. *Alzheimers Res Ther*, 2015. **7**(1): p. 59.


60. Weissberger, G.H., et al., *Diagnostic Accuracy of Memory Measures in Alzheimer's Dementia and Mild Cognitive Impairment: a Systematic Review and Meta-Analysis*. *Neuropsychology review*, 2017. **27**(4): p. 354-388.
61. Zetterberg, H., et al., *Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression*. *JAMA neurology*, 2016. **73**(1): p. 60-67.
62. Guhra, M., et al., *Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data*. *Exp Gerontol*, 2016. **73**: p. 107-13.
63. Nordlund, A., et al., *Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI*. *J Int Neuropsychol Soc*, 2008. **14**(4): p. 582-90.
64. Rolstad, S., et al., *Amyloid-beta(4)(2) is associated with cognitive impairment in healthy elderly and subjective cognitive impairment*. *J Alzheimers Dis*, 2011. **26**(1): p. 135-42.
65. Bendlin, B.B., et al., *CSF T-Tau/Abeta42 predicts white matter microstructure in healthy adults at risk for Alzheimer's disease*. *PLoS One*, 2012. **7**(6): p. e37720.
66. Bertens, D., et al., *Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease*. *Alzheimers Dement*, 2015. **11**(5): p. 511-22.
67. Darreh-Shori, T., et al., *Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease*. *Neurobiol Aging*, 2013. **34**(11): p. 2465-81.
68. Sala-Llonch, R., et al., *Inflammation, Amyloid, and Atrophy in The Aging Brain: Relationships with Longitudinal Changes in Cognition*. *J Alzheimers Dis*, 2017. **58**(3): p. 829-840.
69. Bos, I., et al., *Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum*. *Alzheimers Dement*, 2019. **15**(5): p. 644-654.
70. Sutphen, C.L., et al., *Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age*. *JAMA Neurol*, 2015. **72**(9): p. 1029-42.

## Figures




**Figure 1**

Flow diagram of sample selection




**Figure 2**

Pearson's correlation matrix between CSF markers, age and length of education. Colored squares indicate statistical significance ( $p < 0.05$ ). CSF measures were natural log-transformed




**Figure 3**

Comparison between ROC curves of the two cognitive domains and the CSF marker with the highest area under the curve (AUC) coefficients



**Figure 4**

LASSO linear regression - stability selection analyses for prediction of composite z-scores reflecting a) verbal episodic memory, b) non-verbal episodic memory, c) language, d) processing speed and e) executive functions. Two analyses were created for each domain, one including all participants (n=52) and the other only the CSF AD profile group (n=28). The cut-off selection value was set at 75% and the per-family error rate (PFER) at 1 for all analyses.



**Figure 5**

Scatter plots presenting Pearson's correlations between CSF levels of NFL and verbal episodic memory (a,b), T-tau and verbal episodic memory (c,d), GFAP and processing speed (e,f) and GFAP and executive functions (g,h) within the whole cohort and by CSF profile. \*Cognitive domains were adjusted for covariates (age and education). Without the bottom corner GFAP outlier in the CSF AD profile group,

Pearson's correlations were a slightly lower for f) processing speed ( $r=-0.58$ ,  $p=0.001$ ) and h) executive functions ( $r=-0.28$ ,  $p=0.15$ )

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Additionalfile1cleanversion.docx](#)